Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Becton, Dickinson and Company (BD) SEC filings page for ticker BDX provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New Jersey–incorporated issuer with common stock listed on the New York Stock Exchange, BD files current reports on Form 8-K, annual and quarterly reports, proxy statements and other documents that give investors insight into its financial condition, governance and capital structure.
BD’s recent Form 8-K filings include disclosures on financial results, such as preliminary unaudited revenue and quarterly earnings press releases, as well as corporate events like executive transitions, board appointments and changes in credit facilities. For example, BD has reported the appointment of new directors, the planned transition of its chief financial officer role, and the execution of a third amended and restated revolving credit agreement that provides senior unsecured financing for general corporate purposes. Other 8-K filings describe temporary blackout periods under the BD 401(k) Plan related to a transaction involving Waters Corporation.
Investors can also review BD’s definitive proxy statement on Schedule 14A, which outlines matters for shareholder voting, board composition, executive compensation programs and strategic themes such as the BD2025 and Excellence Unleashed strategies. Debt-related filings, including listings of various series of notes and a Form 25 relating to the removal from listing of 0.034% Notes due 2025, help users understand BD’s capital markets activities. Common stock and several note issues remain registered and listed on the NYSE, as indicated in the filings.
On this page, Stock Titan presents BD’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, such as 10-K and 10-Q reports, 8-K event descriptions and proxy materials. Users can quickly identify information about BD’s revolving credit facilities, leverage covenants, executive changes, shareholder meetings and note listings, while still having the option to review the full original filings from EDGAR for detailed analysis.
Becton, Dickinson and Company (BD) completed the previously announced spin-off of its Biosciences & Diagnostic Solutions business and its combination with Waters Corporation. BD shareholders received approximately 0.135 shares of Waters common stock for each BD share held as of February 5, 2026.
BD received $4 billion of cash from SpinCo. BD expects to use $2 billion for an accelerated share repurchase program and $2 billion for debt repayments, both targeted in the near term subject to market conditions.
Based on Waters’ February 6, 2026 closing price, the transaction valued the Biosciences & Diagnostic Solutions business at $18.8 billion, and BD shareholders owned 39.2% of the combined company on a fully diluted basis. Claire M. Fraser, Ph.D., resigned from BD’s board and joined the Waters board.
Becton, Dickinson and Company (BD) reported fiscal Q1 2026 revenue of $5.25 billion, up 1.6% year over year (0.4% on a currency-neutral basis). GAAP diluted EPS rose to $1.34 from $1.04, while adjusted diluted EPS declined to $2.91 from $3.43, mainly reflecting non-core items and comparison to a strong prior year.
"New BD" revenue, which excludes the Biosciences and Diagnostic Solutions business being combined with Waters Corporation, grew 3.5% (2.5% FX-neutral). Growth was led by Connected Care and Interventional, while Life Sciences declined. The company expects to complete the Waters combination today and affirmed fiscal 2026 New BD guidance of low single-digit FX-neutral revenue growth and adjusted diluted EPS of $12.35 to $12.65, positioning the streamlined portfolio for longer-term earnings and margin expansion.
Becton Dickinson & Co. executive Massimiliano Urbini has filed an initial Form 3 reporting his equity holdings. As EVP & Chief ISC Officer, he beneficially owns 4,133 shares of common stock, including restricted stock units granted under the company’s 2004 equity compensation plan.
He also holds several stock appreciation right awards over common stock: 2,649 rights at an exercise price of $241.10 expiring on 11/26/2031, 2,378 rights at $238.06 expiring on 11/26/2032, 1,843 rights at $238.89 expiring on 11/26/2033, and 1,984 rights at $224.25 expiring on 11/26/2034. These stock appreciation rights vest in four annual installments beginning one year from each grant date.
Becton, Dickinson and Company approved a new Series D Junior Participating Redeemable Preferred Stock in connection with its planned spin-off of Augusta SpinCo Corporation and the Reverse Morris Trust combination with Waters Corporation. Augusta SpinCo will hold BD’s Biosciences and Diagnostic Solutions business.
On January 30, 2026, BD filed a Certificate of Designation for the Series D Preferred Stock. On February 2, 2026, BD entered into exchange agreements with two deferred compensation plan trusts, issuing one Series D Preferred share for each 10,000 BD common shares they held, for an aggregate of 27.5159 Preferred Shares.
The exchange is intended to prevent these trusts from receiving Augusta SpinCo common stock in the planned distribution. The Preferred Shares may be redeemed at BD’s option for BD common shares at a set redemption rate and will automatically be redeemed for BD common shares if the SpinCo distribution under the Reverse Morris Trust is completed.
Becton, Dickinson and Company reorganized its business effective October 1, 2025 into five worldwide segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. Each segment groups distinct product-focused organizational units such as Medication Delivery Solutions, Advanced Patient Monitoring and Urology and Critical Care.
The company explains that the segment reorganization did not change principal product lines. Because Life Sciences combines Diagnostic Solutions and Biosciences, and these businesses are subject to a previously announced combination with Waters Corporation, Life Sciences will be removed from segment reporting after that separation, leaving four reportable segments.
To help investors understand trends under the new structure, BD furnished Exhibit 99.1 with unaudited historical recast segment revenues for fiscal 2025, the quarterly periods in 2025 and comparable prior-year periods, including schedules that detail related non-GAAP revenue measures and adjustments.
Becton, Dickinson and Company director Robert Luther Huffines reported an acquisition of deferred stock rights. On February 4, 2026, he acquired 100 derivative securities described as rights to common stock under the BD Deferred Compensation Plan at a price of $201.91 per right, and now beneficially owns 100 such rights directly.
The rights convert into Becton Dickinson common stock on a one-for-one basis. According to the plan terms, these securities are distributed after his service as a director ends, or on the date or dates he specifies.
Becton, Dickinson and Company director Carrie L. Byington reported acquiring 30 derivative rights to common stock under the BD Deferred Compensation Plan on 02/04/2026. These rights are valued at $201.91 per underlying share and convert into common stock on a one-for-one basis.
Following this transaction, Byington beneficially owns a total of 1,714 rights, held directly. The rights are scheduled to be distributed after her service as a director ends, or on dates she specifies in advance, and the total includes rights gained through dividend reinvestment.
Becton, Dickinson and Company director Christopher Ian Montague Jones acquired additional deferred stock rights under the BD Deferred Compensation Plan. On February 4, 2026, he acquired 272 rights to common stock at a reference price of $201.91 per right. Each right converts into one share of BD common stock. Following this transaction, he beneficially owns 11,649 derivative securities representing rights to BD common stock, held directly. These securities are scheduled to be distributed after his service as a director ends, or on dates he has previously specified, and the total includes rights accumulated through dividend reinvestment.
Becton, Dickinson and Company adopted a new Executive Severance Plan effective January 27, 2026, covering senior management at job level J-G9, including named and other executive officers. The plan provides lump-sum cash severance if employment is terminated without Cause, subject to a release of claims and other conditions.
Cash severance equals 1.5 times base salary and target bonus for the CEO, 1.0 times base salary and target bonus for Executive Leadership Team members, and 1.0 times base salary for Business Unit Presidents and other eligible participants, plus a pro-rated target bonus, COBRA-related payments and up to nine months of outplacement services. Shareholders also approved adding 3,935,000 shares to the 2004 Employee and Director Equity-Based Compensation Plan and re-elected all director nominees, ratified Ernst & Young as auditor, and approved executive compensation on an advisory basis.
The Vanguard Group has filed an amended Schedule 13G reporting beneficial ownership of 36,678,939 shares of Becton Dickinson & Co common stock, representing 12.85% of the class as of the event date of 12/31/2025.
Vanguard reports shared voting power over 2,919,413 shares and shared dispositive power over 36,678,939 shares, with no sole voting or dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of influencing control of Becton Dickinson.
Vanguard explains that, following an internal realignment on January 12, 2026, certain subsidiaries or business divisions that pursue the same investment strategies are expected to report beneficial ownership separately. Vanguard’s clients have rights to dividends and sale proceeds, but no single other person has an interest over 5% of the class.